Finally, the combination of anti-EGFR and anti-VEGF therapy shows better tumor inhibition than single anti-VEGF therapy, which is beneficial to optimize the clinical treatment of NPC. This evidence concerns the gene EGFR and nasopharyngeal carcinoma.